Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
|Articles|November 22, 2016
UK Pathology Services "at Tipping Point"
November 23, 2016
Advertisement
Pathology services in the UK are struggling to cope with the increasing number of patient samples that need to be tested, according to a Cancer Research UK report published today.
A growing and ageing UK population means that more people than ever before are being referred for cancer tests, including biopsies and blood tests, but pathology staff numbers are not growing to meet the rising demand for tests.
The report recommends that action is taken now to address current and future workforce shortfalls, with more tranining and employment of pathology and other diagnostic health professionals.
Advertisement
Related to this article
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
The top barrier to AI adoption among pharma commercial leaders is compliance uncertainty, and the fix may be governance that evaluates one use case at a time.
Brox.AI’s Hamish Brocklebank on the three approaches to digital twins in pharma — and why only one-to-one clones of real individuals deliver true accuracy.
Pathos AI launches multi-year collaborations to build an AI-driven dataset for Alzheimer’s and other neurological diseases.
Advertisement
Advertisement
Trending on PharmExec
1
ANI Pharmaceuticals to Acquire Egetis Therapeutics, Egetis Sells Priority Review Voucher for $190 Million
2
Why Leronlimab Isn’t Just Another Repurposed Drug: Q&A with Dr. Jay Lalezari
3
Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie
4
What Does a Positive Reading for Leronlimab Mean for How the Industry Thinks About Repurposing Old Biologics Into Oncology?
5